J. G. Jacobson

发表

Concentrated insulins: History and critical reappraisal

J. M. Beals, L. Heinemann, J. Beals, 2018, Journal of diabetes.

Predictive Value of Early Changes in Triglycerides and Weight for Longer-Term Changes in Metabolic Measures During Olanzapine, Ziprasidone or Aripiprazole Treatment for Schizophrenia and Schizoaffective Disorder: Post Hoc Analyses of 3 Randomized, Controlled Clinical Trials

R. Conley, M. Case, V. P. Hoffmann, 2010, Journal of clinical psychopharmacology.

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

Honghua H. Jiang, M. Riddle, K. Mace, 2011, Diabetes Care.

Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.

R. Tamura, D. Geller, J. Heiligenstein, 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.

R. Findling, K. Wagner, J. Busner, 2006, Journal of child and adolescent psychopharmacology.

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial

J. Bue-Valleskey, T. Bailey, M. Davies, 2016, Diabetes, obesity & metabolism.

Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.

J. McCracken, R. Findling, K. Wagner, 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women

J. Bishop, B. Fijal, J. Houston, 2011, Psychiatry Research.

Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment

R. Judge, J. G. Jacobson, D. Quail, 2002, International clinical psychopharmacology.

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.

K. Wagner, G. Emslie, J. Heiligenstein, 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder.

E. Dunayevich, A. Green, H. Ascher-Svanum, 2007, The Journal of clinical psychiatry.

Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care.

A. Nyhuis, M. Stensland, J. G. Jacobson, 2007, Journal of affective disorders.

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

T. Hardy, I. Lipkovich, V. P. Hoffmann, 2008, BMC psychiatry.

The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry.

H. Ascher-Svanum, D. Faries, F. Ernst, 2007, Primary care companion to the Journal of clinical psychiatry.

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial

Honghua H. Jiang, Sherry A. Martin, T. Blevins, 2013, Diabetes, obesity & metabolism.

Number Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar Disorder

M. Tohen, Elisabeth K. Degenhardt, V. Sutton, 2009, Journal of clinical psychopharmacology.

Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials.

I. Lipkovich, C. Beasley, V. P. Hoffmann, 2009, Psychopharmacology bulletin.

Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: Data from a clinical study that was terminated early

M. Case, V. P. Hoffmann, J. G. Jacobson, 2009, Schizophrenia Research.

Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia: An Analysis of Correlations With Efficacy, Weight Gain, and Prolactin Concentration

L. Citrome, B. Kinon, R. Bergstrom, 2009, Journal of clinical psychopharmacology.

Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.

W. Herman, J. Buse, Honghua H. Jiang, 2012, Diabetes research and clinical practice.

Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.

W. Herman, J. Buse, Honghua H. Jiang, 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

S. Garg, A. Bhargava, N. Schloot, 2016, Diabetes, obesity & metabolism.

Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.

M. Case, V. P. Hoffmann, J. G. Jacobson, 2012, The Journal of clinical psychiatry.